STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
Two pharmaceutical companies have petitioned the U.S. Supreme Court to restore mail-order access to mifepristone, a key abortion medication, after an appeals court temporarily blocked its delivery. Meanwhile, UCB has acquired Candid Therapeutics for $2 billion upfront, aiming to expand its autoimmune disease therapy pipeline. The deal ends Candid's planned reverse merger with Rallybio, which would have provided a Nasdaq listing and significant financing.
- ▪Danco Laboratories and GenBioPro filed applications with the U.S. Supreme Court to restore mail-order access to mifepristone.
- ▪An appeals court recently blocked deliveries of mifepristone, limiting access especially in states with abortion bans.
- ▪UCB agreed to acquire Candid Therapeutics for $2 billion upfront, with an additional $200 million in potential milestone payments.
- ▪The acquisition gives UCB a pipeline of four T-cell engager candidates, two of which are in early clinical testing.
- ▪Candid Therapeutics has withdrawn from a previously announced reverse merger agreement with Rallybio.
Opening excerpt (first ~120 words) tap to expand
STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news Takeda drug for primary immunodeficiency disease met main goal of a trial Manage alerts for this article Email this article Share this article Alex Hogan/STAT By Ed SilvermanMay 4, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
